USE OF THE CD2 SIGNALING DOMAIN IN SECOND GENERATION CHIMERIC ANTIGEN RECEPTORS

摘要

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain a transmembrane domain a CD2 signaling domain and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR T cells in both negative and positive directions.